News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Takara Bio Reports on Cancer Drug Trial in China


5/5/2008 2:22:13 PM

May 5, 2008 -- Takara Bio Inc. (TSE: 4974) of Japan has begun a collaboration with Tianjin Cancer Institute & Hospital, Tianjin Medical University, under which Tianjin Cancer Institute & Hospital has initiated clinical research of a cancer immunotherapy developed by Takara. The new immunotherapy uses RetroNectin®, Takara’s proprietary recombinant human fibronectin, to expand T-cells. More details...

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES